The Relative Strength (RS) Rating for Omnicell moved up into a higher percentile Tuesday, as it got a lift from 70 to 78.
This exclusive rating from Investor's Business Daily identifies price action with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the trailing 52 weeks holds up against all the other stocks in our database.
Decades of market research shows that the best-performing stocks tend to have an RS Rating of at least 80 as they launch their biggest runs. See if Omnicell can continue to rebound and hit that benchmark.
How To Invest In Stocks In Both Bull And Bear Markets
While now is not an ideal time to buy shares, see if the stock is able to offer and clear an appropriate buy point.
In terms of fundamentals, Omnicell has posted three quarters of increasing earnings growth. Revenue growth has also moved higher over the same time frame.
The company earns the No. 17 rank among its peers in the Medical-Systems/Equipment industry group. Intuitive Surgical, Electromed and Brainsway ADR are among the top 5 highly rated stocks within the group.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
